Opicapone Levodopa Combination for Parkinson's Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease-associated pain, particularly fluctuation-related pain, are inadequate due to limited efficacy of dopaminergic therapies and the peripheral metabolism of levodopa leading to reduced bioavailability and increased pain during 'OFF' periods.
Innovation Solution
The use of opicapone, a third-generation catechol-O-methyltransferase inhibitor, in combination with levodopa to enhance bioavailability and reduce 'OFF' periods, thereby alleviating fluctuation-related pain and associated non-motor symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa is administered to treat Parkinson's disease, then motor symptoms are improved, but peripheral metabolism reduces bioavailability and causes wearing-off periods with increased pain
Solution Approach 1:
The patent uses COMT inhibitors (entacapone, tolcapone, opicapone) as intermediary substances that block the peripheral metabolism of levodopa by inhibiting catechol-O-methyltransferase enzyme. This mediator prevents the breakdown of levodopa in the periphery, thereby increasing its bioavailability and reducing the wearing-off effect without directly affecting the central dopaminergic action
Solution Approach 2:
The patent changes the pharmacokinetic parameters of levodopa by combining it with COMT inhibitors, which alter the metabolism rate and half-life of levodopa. This parameter change increases the area under the curve (AUC) and extends the duration of action, thereby reducing the frequency of dosing and preventing pain during OFF periods
2Object-affected harmful factors
If dopaminergic therapies are used to alleviate PD-associated pain, then pain relief is achieved, but clinical evidence is lacking and treatment efficacy is limited
Solution Approach 1:
The patent implements continuous dopaminergic stimulation by combining levodopa with COMT inhibitors, which maintain stable plasma levels of levodopa throughout the dosing interval. This continuous action prevents the fluctuations that cause pain during OFF periods, providing more reliable and consistent pain relief compared to intermittent dosing
Solution Approach 2:
The patent creates a composite pharmacological regimen by combining levodopa with COMT inhibitors (entacapone, tolcapone, or opicapone). This composite approach leverages the synergistic effects of both substances, where the COMT inhibitor enhances and prolongs the action of levodopa, providing more reliable pain management than either substance alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces fluctuation-related pain and improves non-motor symptoms such as anxiety and depression by increasing levodopa bioavailability, effectively managing pain and motor fluctuations in Parkinson's disease patients.
Implementation Method 1
opicapone, a third-generation catechol-O-methyltransferase inhibitor
Data Source
AI summary
This invention relates to methods for treating pain associated with Parkinson's disease (PD). In particular it relates to the use of opicapone for treating PD-associated pain, especially fluctuation-related pain.